Hypogammaglobulinemia
44% of patients with acute exacerbations of COPD have hypogammaglobulinemia
SAN DIEGO — Immunoglobulin G hypogammaglobulinemia was found in 44.7% of patients with acute exacerbations of COPD receiving triple therapy, according to a presentation here.
Top in allergy/asthma: FDA approves Xolremdi; new law protects kids with allergies
X4 Pharmaceuticals has announced that the FDA approved Xolremdi as a treatment for warts, hypogammaglobulinemia, infections and myelokathexis, also known as WHIM, syndrome, a rare and chronic primary immunodeficiency.
FDA approves mavorixafor for WHIM syndrome
The FDA has approved mavorixafor for treating warts, hypogammaglobulinemia, infections and myelokathexis — or WHIM — syndrome, a rare and chronic primary immunodeficiency, according to a press release from X4 Pharmaceuticals.
Racial, ethnic disparities impact mortality rates among inborn errors of immunity
Racial and ethnic disparities in mortality due to inborn errors of immunity indicate an urgent need to identify and remove barriers in care, according to a study published in The Journal of Allergy and Clinical Immunology.
Mavorixafor reduces infection rates among patients with WHIM syndrome
Daily treatment with mavorixafor improved outcomes among patients with warts, hypogammaglobulinemia, infections and myelokathexis, or WHIM syndrome, in the 4WHIM phase 3 clinical trial, according to the drug’s developer, X4 Pharmaceuticals.